Ipca Laboratories Ltd reported a 9% year-on-year growth in revenue from operations at Rs 2,556.50 crore for Q2 FY26, compared to Rs 2,354.90 crore in the same quarter last year. Total income for the September quarter stood at Rs 2,584.36 crore.
The company posted a 23% YoY increase in EBITDA (before forex and exceptional items), which came in at Rs 554.31 crore against Rs 449.83 crore last year. Other income rose slightly to Rs 27.86 crore from Rs 26.26 crore.
Finance cost declined 13% YoY to Rs 19.61 crore, while depreciation and amortisation expenses increased 3% to Rs 103.33 crore. Ipca also reported exceptional expenses of Rs 58.26 crore during the quarter.
Net profit surged 23% YoY to Rs 282.57 crore, compared to Rs 229.48 crore in Q2 FY25. Tax expenses rose 9% to Rs 108.08 crore.
Earnings per share before exceptional items stood at Rs 12.35 versus Rs 9.05 last year, while EPS after exceptional items was Rs 11.14 compared to Rs 9.05 in Q2 FY25.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
